The National Pharmaceutical Pricing Authority introduced a Trade Margin Rationalisation order capping markups on select anti-cancer drugs. The move aims to improve affordability but may face structural limitations in addressing systemic access issues.
NPPA Caps Trade Margins to Improve Access to Anti-Cancer Drugs
The National Pharmaceutical Pricing Authority (NPPA) recently issued a Trade Margin Rationalisation (TMR) order placing caps on wholesale and retail markups for key anti-cancer medications. The policy targets high out-of-pocket costs by limiting trade margins on both scheduled and non-scheduled cancer drugs, aiming to reduce final consumer prices without altering maximum retail prices (MRPs).
Under the order, wholesale margins are capped at 12% and retail margins at 16% for specified formulations. The NPPA invoked its powers under Para 20 of the Drugs Prices Control Order (DPCO), 2013, which allows regulation of market-based pricing distortions. However, critics argue that capping margins does not address supply chain inefficiencies or underpricing at the manufacturer level, likening the policy to “taping a cracked pipe” rather than systemic reform.
Practical Impact on Pharma Pricing Strategy
For legal practitioners, this order underscores the expanding regulatory role of the NPPA beyond bulk drug price controls. Companies must now assess compliance with margin caps even for non-scheduled drugs. The decision may prompt increased litigation over what constitutes fair trade margins, especially in markets with fragmented distribution networks. Long-term affordability, however, remains contingent on parallel reforms in health insurance and procurement.
Citations
- Drugs Prices Control Order, 2013, Para 20
